Biochemical relationship between leiomyosarcoma and peroxiredoxin-6 expression level: Clinical implications
NOPR - NISCAIR Online Periodicals Repository
View Archive InfoField | Value | |
Title |
Biochemical relationship between leiomyosarcoma and peroxiredoxin-6 expression level: Clinical implications
|
|
Creator |
Herkiloglu, Dilsad
Gokce, Sefik Kaygusuz, Ecmel Isık Cevik, Ozge Ahmad, Sarfraz |
|
Subject |
Biomarker
Clinical relevance Histopathology Leomyosarcoma Myoma Peroxiredoxin-6 Prognosis |
|
Description |
552-527
Uterine leiomyosarcomas are tumors with a heterogeneous genetic profiles that respond very poorly to cytotoxic chemotherapy with aggressive progression. We aimed to show the status of peroxiredoxin 6 as a biomarker in leiomyosarcoma progression.Study included 12 patients diagnosed with "leiomyosarcoma" and 13 patients diagnosed with "myoma" (as control) after histopathological examinations of clinical samples. Peroxiredoxin-6 gene expression and protein levels were evaluated on the tumor preparations (blocks) utilizing ELISA and PCR methods.Peroxiredoxin-6 protein was mainly localized in the cytoplasm of leiomyosarcoma cells, and the expression of peroxiredoxin-6 was significantly increased in cancerous tissues compared to normal myoma tissues (3.33±1.7 vs. 2.03±1.07fold change; P= 0.031). Peroxiredoxin-6 tissue protein levels were also significantly higher in leiomyosarcoma cases (100.54±66.86 vs. 183.72±64.54 pg/μg protein; P= 0.005). Our findings demonstrate that peroxiredoxin-6 plays a vital role in the emergence and development of leiomyosarcoma and that peroxiredoxin-6 level assessments can be used as a biomarker in guiding better prognosis andtreatment plans while managing leiomyosarcoma. |
|
Date |
2022-05-26T11:36:43Z
2022-05-26T11:36:43Z 2022-05 |
|
Type |
Article
|
|
Identifier |
0975-0959 (Online); 0301-1208 (Print)
http://nopr.niscair.res.in/handle/123456789/59770 |
|
Language |
en
|
|
Publisher |
NIScPR-CSIR, India
|
|
Source |
IJBB Vol.59(5) [May 2022]
|
|